A majority of patients in the study had complete remission of disease within bone marrow with the combination therapy.
Heme Today
Heme Today covers the latest news and analyses in bleeding, clotting, red blood cell, and iron disorders for hematologists and oncologists focused on bleeding disorders.
Advertisement
Latest News
A phase II trial evaluated use of the thrombopoietin receptor agonist in patients with at least one prior therapy.
Most of the research performed up to this point on the influence of clonal dynamics in MDS has focused on high-risk disease.
A recent study brings insight regarding the best timing for this CAR-T therapy in patients with prior BCMA-directed therapy.
Dr. Theodore Wun and Dr. Olubusola Oluwole investigated the causes of rising stroke rates among pediatric and adult patients.
Efficacy and safety primary analysis findings are reported from the international, open-label FREEDOM2 trial.
A new study addresses the need for data on treatment outcomes in patients younger than 12 years of age.
Levels for certain inflammation biomarkers in patients with MDS were similar to in patients with autoinflammatory disorders.
In pediatric, adolescent, and young adult patients, hematopoietic stem cell transplant was found to bolster overall survival.
The most common serious treatment-emergent adverse event among patients receiving either therapy was pneumonia.
A phase II trial calculated a 4-year event-free survival rate of 96% and overall survival rate of 100% from the combination.
Advertisement
Blood Cancer Awareness Month
A phase II trial calculated a 4-year event-free survival rate of 96% and overall survival rate of 100% from the combination.
Differences were identified between patient racial groups and by urban versus rural populations.
A magnetic resonance imaging study has compared tissue iron levels and biventricular function between the two conditions.
MDS Roundtables
Expert Interviews on Hematology
Conference Coverage
Heme Today reports from the EHA 2024 Hybrid Congress the latest findings in hematology research and management.
Highlighting the latest news and experts in pediatric hematology and oncology from the 2024 ASPHO Conference in Seattle.
Our editors are covering data on transplantation and cellular therapies from the 2024 Tandem Meetings of ASTCT® and ...
The editors of Heme Today review major presentations on classical hematology from the 2023 ASH Annual Meeting & ...
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.